FDA Medical Error Proposal Requires Reporting “Near-Misses” Within 15 Days
Executive Summary
FDA's proposed safety reporting requirements would require reports on "near misses" of medical errors within 15 days
You may also be interested in...
FDA’s Adverse Event Reporting Rule Would Generate “Noise,” PhRMA Says
FDA's proposed rule on suspected adverse events would generate excess reports without increasing the value of the surveillance, the Pharmaceutical Research & Manufacturers of America says
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005